Full Press Release Details
arGEN-X’ Partner RuiYi, Inc. Announces First Human Dosing of Gerilimzumab, A Novel SIMPLE Antibody™ Against IL-6.
ARGX
arGEN-X’ Partner RuiYi, Inc. Announces First Human Dosing of Gerilimzumab, A Novel SIMPLE Antibody™ Against IL-6
Key Takeaway: arGEN-X’ Partner RuiYi, Inc. Announces First Human Dosing of Gerilimzumab, A Novel SIMPLE Antibody™ Against IL-6
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+36%
120-day peak, hindsight
Typical move
4.7%
average across 12 past catalysts
Lead asset
Empasiprubart
Phase 2 · AChR-Ab Seropositive Generalized Myasthenia Gravis